{
    "hands_on_practices": [
        {
            "introduction": "The diagnosis of Disseminated Intravascular Coagulation (DIC) in critically ill surgical patients requires a systematic approach to distinguish it from other coagulopathies. To move beyond clinical suspicion to an objective diagnosis, the International Society on Thrombosis and Hemostasis (ISTH) developed a robust scoring system. This exercise  provides practice in applying this crucial tool, which translates key laboratory parameters—platelet count, prothrombin time, fibrinogen, and D-dimer—into a quantitative score to determine if a patient meets the criteria for overt DIC.",
            "id": "5111327",
            "problem": "A $68$-year-old patient on postoperative day $2$ after emergency sigmoid colectomy for feculent peritonitis is in vasopressor-dependent septic shock with diffuse oozing from central line sites. You are asked to assess for overt disseminated intravascular coagulation (DIC) using the International Society on Thrombosis and Hemostasis (ISTH) overt DIC scoring system.\n\nCurrent laboratory data:\n- Platelet count: $38 \\times 10^{9}/\\mathrm{L}$\n- Prothrombin time (PT): control $12.0\\,\\mathrm{s}$, patient $18.5\\,\\mathrm{s}$\n- Fibrinogen: $0.80\\,\\mathrm{g/L}$\n- D-dimer (fibrinogen equivalent units (FEU)): $9.6\\,\\mathrm{mg/L}$; laboratory upper limit of normal (ULN) $0.50\\,\\mathrm{mg/L}$\n\nUse the ISTH overt DIC scoring framework, which assigns points based on the following four domains:\n- Platelet count: $\\geq 100 \\times 10^{9}/\\mathrm{L} \\rightarrow 0$; $\\geq 50$ to $ 100 \\times 10^{9}/\\mathrm{L} \\rightarrow 1$; $ 50 \\times 10^{9}/\\mathrm{L} \\rightarrow 2$.\n- Prolongation of PT beyond control: $ 3\\,\\mathrm{s} \\rightarrow 0$; $\\geq 3$ to $\\leq 6\\,\\mathrm{s} \\rightarrow 1$; $> 6\\,\\mathrm{s} \\rightarrow 2$.\n- Fibrin-related markers (e.g., D-dimer): no increase (at or below ULN) $\\rightarrow 0$; moderate increase (above ULN but $ 3 \\times \\mathrm{ULN}$) $\\rightarrow 2$; strong increase ($\\geq 3 \\times \\mathrm{ULN}$) $\\rightarrow 3$.\n- Fibrinogen: $\\geq 1.0\\,\\mathrm{g/L} \\rightarrow 0$; $ 1.0\\,\\mathrm{g/L} \\rightarrow 1$.\n\nCompute the total ISTH overt DIC score for this patient. Although the clinical interpretation threshold for overt DIC is conventionally $\\geq 5$, your final response must be only the numerical total score. Report the integer score; do not include units. No rounding is necessary.",
            "solution": "The problem is valid as it is scientifically grounded, well-posed, and objective. It provides a clear clinical scenario, a complete set of laboratory data, and a well-defined scoring algorithm—the International Society on Thrombosis and Hemostasis (ISTH) overt disseminated intravascular coagulation (DIC) scoring system. The task is to compute a total score by applying this algorithm to the given data. The calculation is a direct application of the provided rules.\n\nThe total ISTH score is the sum of scores from four domains: platelet count, prothrombin time prolongation, fibrin-related markers, and fibrinogen level. We will calculate the score for each domain sequentially and then sum them.\n\n1.  **Platelet Count Score**\n    The patient's platelet count is given as $38 \\times 10^{9}/\\mathrm{L}$.\n    The ISTH scoring rules for platelet count are:\n    - $\\geq 100 \\times 10^{9}/\\mathrm{L} \\rightarrow 0$ points\n    - $\\geq 50$ to $ 100 \\times 10^{9}/\\mathrm{L} \\rightarrow 1$ point\n    - $ 50 \\times 10^{9}/\\mathrm{L} \\rightarrow 2$ points\n    The patient's value of $38 \\times 10^{9}/\\mathrm{L}$ is less than $50 \\times 10^{9}/\\mathrm{L}$.\n    Therefore, the score for this domain is $2$.\n\n2.  **Prothrombin Time (PT) Prolongation Score**\n    The patient's prothrombin time (PT) is $18.5\\,\\mathrm{s}$, and the control PT is $12.0\\,\\mathrm{s}$.\n    The prolongation of PT is the difference:\n    $$ \\Delta \\mathrm{PT} = \\mathrm{Patient's\\ PT} - \\mathrm{Control\\ PT} = 18.5\\,\\mathrm{s} - 12.0\\,\\mathrm{s} = 6.5\\,\\mathrm{s} $$\n    The ISTH scoring rules for PT prolongation are:\n    - $ 3\\,\\mathrm{s} \\rightarrow 0$ points\n    - $\\geq 3$ to $\\leq 6\\,\\mathrm{s} \\rightarrow 1$ point\n    - $> 6\\,\\mathrm{s} \\rightarrow 2$ points\n    The calculated prolongation of $6.5\\,\\mathrm{s}$ is greater than $6\\,\\mathrm{s}$.\n    Therefore, the score for this domain is $2$.\n\n3.  **Fibrin-Related Markers (D-dimer) Score**\n    The patient's D-dimer level is $9.6\\,\\mathrm{mg/L}$. The laboratory's upper limit of normal (ULN) for D-dimer is $0.50\\,\\mathrm{mg/L}$.\n    The ISTH scoring rules for fibrin-related markers are:\n    - No increase (at or below ULN) $\\rightarrow 0$ points\n    - Moderate increase (above ULN but $ 3 \\times \\mathrm{ULN}$) $\\rightarrow 2$ points\n    - Strong increase ($\\geq 3 \\times \\mathrm{ULN}$) $\\rightarrow 3$ points\n    We must determine if the increase is moderate or strong. The threshold for a strong increase is $3$ times the ULN:\n    $$ 3 \\times \\mathrm{ULN} = 3 \\times 0.50\\,\\mathrm{mg/L} = 1.5\\,\\mathrm{mg/L} $$\n    The patient's D-dimer of $9.6\\,\\mathrm{mg/L}$ is greater than or equal to the threshold of $1.5\\,\\mathrm{mg/L}$. This constitutes a strong increase.\n    Therefore, the score for this domain is $3$.\n\n4.  **Fibrinogen Score**\n    The patient's fibrinogen level is $0.80\\,\\mathrm{g/L}$.\n    The ISTH scoring rules for fibrinogen are:\n    - $\\geq 1.0\\,\\mathrm{g/L} \\rightarrow 0$ points\n    - $ 1.0\\,\\mathrm{g/L} \\rightarrow 1$ point\n    The patient's value of $0.80\\,\\mathrm{g/L}$ is less than $1.0\\,\\mathrm{g/L}$.\n    Therefore, the score for this domain is $1$.\n\n**Total ISTH Score**\nThe total score is the sum of the scores from the four domains:\n$$ \\text{Total Score} = (\\text{Platelet Score}) + (\\text{PT Score}) + (\\text{D-dimer Score}) + (\\text{Fibrinogen Score}) $$\n$$ \\text{Total Score} = 2 + 2 + 3 + 1 = 8 $$\nThe final computed ISTH overt DIC score for this patient is $8$.",
            "answer": "$$\\boxed{8}$$"
        },
        {
            "introduction": "Diagnosing DIC is only the first step; effective management requires a deep understanding of the underlying pathophysiology driving the coagulopathy. In surgical settings like major trauma, the \"triad of death\"—hypothermia, acidosis, and coagulopathy—creates a complex, rapidly evolving picture. This exercise  challenges you to reason from first principles of enzyme kinetics and mass action to predict the specific viscoelastic signature (ROTEM/TEG) that results from these combined insults. Mastering this skill allows a clinician to anticipate laboratory findings and proactively assemble a multifaceted therapeutic strategy that addresses each component of the coagulopathy.",
            "id": "5111269",
            "problem": "A $28$-year-old man with blunt polytrauma undergoes emergent damage-control laparotomy for hemorrhagic shock. He arrives to the operating room with core temperature $T=33.5^\\circ \\mathrm{C}$, arterial $\\mathrm{pH}=7.12$, serum lactate $8.5\\,\\mathrm{mmol/L}$, ionized calcium $0.90\\,\\mathrm{mmol/L}$, hemoglobin $7.2\\,\\mathrm{g/dL}$, platelet count $68\\times 10^9/\\mathrm{L}$, and Clauss fibrinogen $120\\,\\mathrm{mg/dL}$ after receiving $5\\,\\mathrm{L}$ of isotonic crystalloid and $6$ units of packed red blood cells en route. Massive transfusion protocol has been activated but fresh frozen plasma and platelets have not yet arrived. Viscoelastic testing is being set up, but the surgical team must anticipate the likely pattern to guide immediate corrective therapy. \n\nUse first principles about enzyme kinetics and mass action to reason from the following foundations:\n- Reaction rates of protease-mediated cascades decrease as temperature decreases per the Arrhenius relationship $k \\propto e^{-E_a/(RT)}$, and many biological reaction systems exhibit a temperature coefficient $Q_{10}\\approx 2$.\n- Protease activity and fibrinogen polymerization show strong $\\mathrm{pH}$-dependence, with activity falling as $\\mathrm{pH}$ decreases from physiologic values.\n- Dilution lowers the concentration of coagulation factors and platelets, reducing the probability of productive collisions and assembly of enzyme complexes per the law of mass action.\n\nBased on these principles and the clinical context of early trauma-associated disseminated intravascular coagulation (DIC) physiology, which option best predicts the combined pattern on Rotational Thromboelastometry (ROTEM) and Thromboelastography (TEG) and outlines the most appropriate immediate corrective measures? Rotational Thromboelastometry (ROTEM) parameters to consider include extrinsically activated clotting time ($EXTEM$ $CT$), clot formation time ($CFT$), $\\alpha$-angle, maximum clot firmness ($MCF$), and lysis index at $30$ minutes ($LI30$) or maximum lysis ($ML$). Thromboelastography (TEG) parameters to consider include reaction time ($R$), $K$ time, $\\alpha$-angle, maximum amplitude ($MA$), and lysis at $30$ minutes ($LY30$).\n\nA. Anticipate delayed initiation and weak clot with hyperfibrinolysis: ROTEM shows prolonged $EXTEM$ $CT$, prolonged $CFT$, decreased $\\alpha$-angle, markedly reduced $EXTEM$ $MCF$; $FIBTEM$ $MCF$ is low; $EXTEM$ has increased lysis (low $LI30$ or high $ML$). TEG shows prolonged $R$ and $K$, decreased $\\alpha$-angle, low $MA$, and elevated $LY30$. Immediate corrective bundle: active rewarming to $36^\\circ \\mathrm{C}$ with forced-air and warmed infusions; balanced hemostatic resuscitation minimizing further crystalloid, with early plasma and platelets (targeting an approximate $1\\!:\\!1\\!:\\!1$ ratio of red blood cells:plasma:platelets) until guided by viscoelastic results; fibrinogen repletion with cryoprecipitate or fibrinogen concentrate to target fibrinogen $\\ge 200\\,\\mathrm{mg/dL}$ (or $FIBTEM$ $MCF$ $\\ge 10$–$12\\,\\mathrm{mm}$); tranexamic acid (TXA) for hyperfibrinolysis; intravenous calcium to maintain ionized calcium $1.1\\,\\mathrm{mmol/L}$; rapid surgical hemostasis and correction of acidosis by restoring perfusion.\n\nB. Anticipate hypercoagulability with rapid clot and strong firmness: ROTEM shows shortened $EXTEM$ $CT$ and increased $MCF$ with minimal lysis; TEG shows shortened $R$ and increased $MA$ with low $LY30$. Immediate corrective bundle: systemic unfractionated heparin infusion to prevent microthrombosis and induce controlled hypothermia to $32^\\circ \\mathrm{C}$ to limit metabolic demand.\n\nC. Anticipate factor deficiency without structural weakness: ROTEM shows prolonged $EXTEM$ $CT$ with normal $FIBTEM$ $MCF$ and normal lysis; TEG shows prolonged $R$ with normal $MA$ and $LY30$. Immediate corrective bundle: four-factor prothrombin complex concentrate (PCC) as sole factor replacement; defer plasma, platelets, and fibrinogen; avoid antifibrinolytics; permissive hypothermia until bleeding controlled.\n\nD. Anticipate normal initiation with isolated fibrin weakness and no fibrinolysis: ROTEM shows normal $EXTEM$ $CT$ with low $FIBTEM$ $MCF$ and normal $LI30$; TEG shows normal $R$ with low $MA$ and low $LY30$. Immediate corrective bundle: desmopressin to augment platelet adhesion and recombinant activated factor VII (rFVIIa) early to achieve hemostasis; avoid plasma and TXA.\n\nE. Anticipate delayed initiation and weak clot with fibrinolysis shutdown: ROTEM shows prolonged $EXTEM$ $CT$, low $MCF$, and very high $LI30$ (minimal lysis); TEG shows prolonged $R$, low $MA$, and $LY30$ near $0\\%$. Immediate corrective bundle: avoid TXA; give red blood cells and vasopressors only; rewarming optional once surgical control is achieved.\n\nSelect the single best option.",
            "solution": "The problem statement is scientifically grounded, well-posed, and objective. All provided data and principles are consistent with established medical and biochemical facts concerning trauma-induced coagulopathy. The patient exhibits the classic \"triad of death\": hypothermia, acidosis, and coagulopathy, exacerbated by dilutional resuscitation. The problem is valid.\n\nThe solution requires synthesizing the effects of the patient's physiological state on the coagulation cascade, as measured by Rotational Thromboelastometry (ROTEM) or Thromboelastography (TEG), and identifying the appropriate corrective actions.\n\n**Derivation from First Principles**\n\n1.  **Effect of Hypothermia ($T=33.5^\\circ \\mathrm{C}$):** The coagulation cascade consists of enzyme-catalyzed reactions. The Arrhenius relationship, $k \\propto e^{-E_a/(RT)}$, dictates that reaction rates ($k$) decrease as absolute temperature ($T$) decreases. The stated $Q_{10} \\approx 2$ implies that for every $10^\\circ \\mathrm{C}$ decrease in temperature, reaction rates are halved. The patient's hypothermia ($33.5^\\circ \\mathrm{C}$ vs. a normal of ~$37^\\circ \\mathrm{C}$) will slow all enzymatic steps of coagulation, from initiation (factor activation) to propagation. This will manifest as a delayed onset of clot formation.\n    *   *Predicted VET effect:* Prolonged ROTEM clotting time ($CT$) and TEG reaction time ($R$).\n\n2.  **Effect of Acidosis ($\\mathrm{pH}=7.12$):** The problem states that protease activity and fibrinogen polymerization are strongly pH-dependent and decrease with acidity. The patient's severe acidosis will impair the function of coagulation factor proteases, further slowing the cascade. Critically, it also directly interferes with the non-enzymatic polymerization of fibrin monomers into a stable fibrin mesh.\n    *   *Predicted VET effect:* Contributes to prolonged $CT$/$R$ and slows the rate of clot formation, reflected as a prolonged ROTEM clot formation time ($CFT$) / TEG $K$ time and a decreased $\\alpha$-angle. The impaired polymerization directly leads to a weaker clot, reflected as a decreased ROTEM maximum clot firmness ($MCF$) / TEG maximum amplitude ($MA$).\n\n3.  **Effect of Dilution and Consumption (Law of Mass Action):** The patient received $5\\,\\mathrm{L}$ of crystalloid and $6$ units of packed red blood cells (PRBCs) without replacement of plasma or platelets. This leads to profound dilution of coagulation factors and platelets. The law of mass action states that reaction rates are proportional to the concentration of reactants.\n    *   *Dilution of Factors:* The reduced concentration of coagulation factors slows the rate of formation of enzyme complexes (e.g., tenase, prothrombinase), further prolonging the initiation and propagation phases.\n    *   *Dilution/Consumption of Platelets and Fibrinogen:* The provided data confirm thrombocytopenia (platelet count $68\\times 10^9/\\mathrm{L}$) and hypofibrinogenemia (fibrinogen $120\\,\\mathrm{mg/dL}$). Platelets form the primary structural scaffold of the clot, and fibrin provides the stabilizing mesh. Deficiencies in both will severely compromise the ultimate clot strength. The low fibrinogen level specifically predicts a low ROTEM $FIBTEM$ $MCF$.\n    *   *Predicted VET effect:* Contributes to prolonged $CT$/$R$, prolonged $CFT$/$K$, and decreased $\\alpha$-angle. The thrombocytopenia and hypofibrinogenemia are the primary drivers of a markedly reduced $MCF$/$MA$.\n\n4.  **Effect of Hypocalcemia (Ionized Calcium $0.90\\,\\mathrm{mmol/L}$):** Calcium ions ($\\mathrm{Ca}^{2+}$) are essential cofactors for the function of coagulation factors II, VII, IX, and X. The patient's hypocalcemia will further impair the enzymatic cascade, exacerbating the effects of hypothermia, acidosis, and dilution.\n    *   *Predicted VET effect:* Contributes to prolonged $CT$/$R$.\n\n5.  **Effect of Hyperfibrinolysis:** The clinical context of early, shock-associated traumatic coagulopathy involves massive release of tissue plasminogen activator (t-PA) from injured endothelium, overwhelming the body's natural inhibitors and leading to systemic hyperfibrinolysis (accelerated clot breakdown).\n    *   *Predicted VET effect:* Increased clot lysis, reflected as a low ROTEM lysis index at $30$ minutes ($LI30$) or high maximum lysis ($ML$), and a high TEG lysis at $30$ minutes ($LY30$).\n\n**Synthesis of the Predicted VET Pattern:**\nCombining these effects, the anticipated pattern is global coagulation failure:\n- **Initiation:** Prolonged (long $CT$/$R$) due to hypothermia, acidosis, dilution of factors, hypocalcemia.\n- **Propagation:** Slow (long $CFT$/$K$, low $\\alpha$-angle) due to the same reasons.\n- **Clot Strength:** Markedly reduced (low $MCF$/$MA$) due to thrombocytopenia, hypofibrinogenemia, and acidosis-impaired polymerization.\n- **Stability:** Poor (high lysis) due to hyperfibrinolysis.\n\nThis pattern represents a classic \"unwound\" or \"exploded\" thromboelastogram.\n\n**Appropriate Immediate Corrective Measures:**\nThe therapeutic strategy must systematically reverse each identified pathophysiological defect:\n- Address hypothermia with active rewarming.\n- Address factor, platelet, and fibrinogen deficiencies with balanced hemostatic resuscitation (plasma, platelets, and a fibrinogen source like cryoprecipitate or concentrate) in a balanced ratio (e.g., $1\\!:\\!1\\!:\\!1$), and minimize further dilution with crystalloids.\n- Address hyperfibrinolysis with an antifibrinolytic agent like tranexamic acid (TXA).\n- Address hypocalcemia with intravenous calcium supplementation.\n- Address the underlying cause by achieving rapid surgical hemostasis and correcting the acidosis by restoring systemic perfusion.\n\n**Option-by-Option Analysis**\n\n**A. Anticipate delayed initiation and weak clot with hyperfibrinolysis... Immediate corrective bundle: active rewarming... balanced hemostatic resuscitation... fibrinogen repletion... tranexamic acid (TXA)... intravenous calcium...**\n- *Pattern Prediction:* The predicted VET pattern (prolonged $CT$/$CFT$, low $\\alpha$-angle/$MCF$, high lysis) is a perfect match for the derivation from first principles.\n- *Corrective Measures:* The proposed bundle systematically addresses every identified defect: hypothermia, component deficiencies (factors, platelets, fibrinogen), hyperfibrinolysis, and hypocalcemia, while acknowledging the need for definitive surgical control and improved perfusion.\n- *Verdict:* **Correct**.\n\n**B. Anticipate hypercoagulability... Immediate corrective bundle: systemic unfractionated heparin infusion... induce controlled hypothermia...**\n- *Pattern Prediction:* This suggests a state of hypercoagulability (short $CT$/$R$, high $MCF$/$MA$), which is the opposite of what is predicted by the patient's state of hypothermia, acidosis, and dilution.\n- *Corrective Measures:* Administering an anticoagulant (heparin) and worsening hypothermia are directly contraindicated and would be lethal.\n- *Verdict:* **Incorrect**.\n\n**C. Anticipate factor deficiency without structural weakness... Immediate corrective bundle: four-factor prothrombin complex concentrate (PCC) as sole factor replacement... permissive hypothermia...**\n- *Pattern Prediction:* This incorrectly assumes normal clot strength (normal $MCF$/$MA$ and $FIBTEM$ $MCF$) and normal lysis, ignoring the profound effects of thrombocytopenia, hypofibrinogenemia, and acidosis.\n- *Corrective Measures:* Using PCC alone fails to replace critical components like fibrinogen, platelets, and other factors (e.g., Factor V). \"Permissive hypothermia\" is harmful.\n- *Verdict:* **Incorrect**.\n\n**D. Anticipate normal initiation with isolated fibrin weakness and no fibrinolysis... Immediate corrective bundle: desmopressin to augment platelet adhesion and recombinant activated factor VII (rFVIIa) early...**\n- *Pattern Prediction:* This incorrectly assumes normal initiation (normal $CT$/$R$), which is impossible given the combined insults. It also incorrectly assumes no hyperfibrinolysis.\n- *Corrective Measures:* Desmopressin has no role here. Early rFVIIa without repleting substrates (fibrinogen, platelets) is ineffective and inappropriate. Avoiding plasma and TXA is incorrect.\n- *Verdict:* **Incorrect**.\n\n**E. Anticipate delayed initiation and weak clot with fibrinolysis shutdown... Immediate corrective bundle: avoid TXA; give red blood cells and vasopressors only; rewarming optional...**\n- *Pattern Prediction:* This correctly identifies delayed initiation and weak clot but misidentifies the fibrinolytic state. While fibrinolysis shutdown can occur in trauma, the classic *early* picture in severe shock is hyperfibrinolysis.\n- *Corrective Measures:* Avoiding TXA would be appropriate for shutdown but is incorrect for the more likely state of hyperfibrinolysis. Resuscitating with only RBCs and vasopressors ignores the coagulopathy and worsens dilution. Making rewarming \"optional\" is a grievous error.\n- *Verdict:* **Incorrect**.\n\nBased on a rigorous application of the provided principles to the clinical data, Option A provides the most accurate prediction of the VET pattern and the most comprehensive and correct set of immediate therapeutic interventions.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "An effective DIC management plan often hinges on precise, goal-directed replacement of depleted coagulation factors and platelets. Hypofibrinogenemia is a key driver of poor clot strength and must be corrected aggressively. This hands-on calculation  provides practice in determining the required dose of cryoprecipitate to reach a target fibrinogen level. It emphasizes a crucial aspect of clinical reasoning in critical care: designing a therapeutic plan that is robust to physiological variability by planning for the \"worst-case\" or least effective response, thereby ensuring the therapeutic goal is achieved.",
            "id": "5111345",
            "problem": "A postoperative patient with Disseminated Intravascular Coagulation (DIC) presents with clinically significant bleeding and a laboratory fibrinogen concentration of $90$ mg/dL. In systemic surgical care, an empiric transfusion approach is used where each unit of cryoprecipitate is observed to increase plasma fibrinogen by a variable amount in the interval $[5,10]$ mg/dL due to inter-patient heterogeneity in plasma volume, fibrinogen distribution, and ongoing consumption. The patient weighs $80$ kg. The institutional target for active hemorrhage in DIC is to achieve a fibrinogen concentration of at least $150$ mg/dL immediately after transfusion, and the dosing strategy must be robust to the lowest plausible per-unit effect.\n\nStarting from first principles, use the definition of concentration change and worst-case design logic to derive the minimum integer number of cryoprecipitate units needed so that, regardless of the variability within the stated range, the post-transfusion fibrinogen concentration will be at least $150$ mg/dL. Assume negligible ongoing fibrinogen consumption during the short interval between transfusion and measurement and that the per-unit increment is independent and additive. Report the final answer as the minimum integer number of cryoprecipitate units required. No rounding instruction is needed beyond taking the least integer that satisfies the condition.",
            "solution": "The problem requires the determination of the minimum integer number of cryoprecipitate units needed to raise a patient's plasma fibrinogen concentration from an initial level to a specified target level, under a worst-case scenario for the therapeutic effect of each unit.\n\nLet us begin by defining the variables from first principles.\nThe initial fibrinogen concentration is denoted by $C_i$.\nThe target fibrinogen concentration is denoted by $C_t$.\nThe number of cryoprecipitate units to be transfused is a positive integer, $N$.\nThe increase in fibrinogen concentration per unit of cryoprecipitate is $\\Delta C_{\\text{unit}}$.\n\nFrom the problem statement, we are given:\nThe initial concentration, $C_i = 90$ mg/dL.\nThe therapeutic goal is to achieve a final concentration, $C_f$, such that $C_f \\ge C_t$, where the target is $C_t = 150$ mg/dL.\nThe effect of a single unit of cryoprecipitate is variable, with the concentration increase $\\Delta C_{\\text{unit}}$ falling within the closed interval $[5, 10]$ mg/dL. Thus, $5 \\le \\Delta C_{\\text{unit}} \\le 10$.\n\nThe problem states that the per-unit increments are independent and additive. Therefore, the total increase in concentration from transfusing $N$ units is the product of the number of units and the increase per unit:\n$ \\Delta C_{\\text{total}} = N \\cdot \\Delta C_{\\text{unit}} $\nThe final concentration, $C_f$, after transfusion is the sum of the initial concentration and the total increase:\n$ C_f = C_i + \\Delta C_{\\text{total}} = C_i + N \\cdot \\Delta C_{\\text{unit}} $\nThe clinical objective requires that the final concentration be at least the target concentration:\n$ C_f \\ge C_t $\nSubstituting the expression for $C_f$, we obtain the governing inequality:\n$ C_i + N \\cdot \\Delta C_{\\text{unit}} \\ge C_t $\nThe problem specifies that the dosing strategy must be \"robust to the lowest plausible per-unit effect.\" This is a worst-case design constraint. To guarantee that the target concentration of $150$ mg/dL is met or exceeded, we must assume that each unit of cryoprecipitate provides the minimum possible therapeutic benefit. This corresponds to the lower bound of the given interval for $\\Delta C_{\\text{unit}}$.\n$ (\\Delta C_{\\text{unit}})_{\\text{worst}} = 5 \\text{ mg/dL} $\nWe must solve the inequality for $N$ using this worst-case value for $\\Delta C_{\\text{unit}}$ to ensure the condition is satisfied regardless of the actual inter-patient variability.\nSubstituting the known values into the inequality:\n$ 90 + N \\cdot 5 \\ge 150 $\nNow, we solve for $N$. First, isolate the term containing $N$:\n$ 5N \\ge 150 - 90 $\n$ 5N \\ge 60 $\nNext, divide by $5$ to solve for $N$:\n$ N \\ge \\frac{60}{5} $\n$ N \\ge 12 $\nThe variable $N$ represents the number of cryoprecipitate units, which must be an integer. The inequality $N \\ge 12$ indicates that $12$ or more units are required. The problem asks for the minimum integer number of units that satisfies this condition. The smallest integer value for $N$ that is greater than or equal to $12$ is $12$.\n\nThe patient's weight of $80$ kg is supplementary information that is not required for the calculation, as the therapeutic effect is already specified in terms of concentration change (mg/dL), which implicitly accounts for the patient's plasma volume.\n\nTherefore, starting from the principle of additive concentration changes and applying worst-case analysis as mandated, the minimum integer number of cryoprecipitate units required is $12$.",
            "answer": "$$\n\\boxed{12}\n$$"
        }
    ]
}